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Excess Mortality and Cardiovascular Events in Patients
Surviving Subarachnoid Hemorrhage
A Nationwide Study in Sweden
Dennis J. Nieuwkamp, MD; Ale Algra, MD; Paul Blomqvist, MD, PhD; Johanna Adami, MD, MPH, PhD;
Erik Buskens, MD; Hendrik Koffijberg, PhD; Gabrie¨l J.E. Rinkel, MD
Background and Purpose—Survivors of aneurysmal subarachnoid hemorrhage (SAH) may have an increased risk of
cardiovascular events because of shared risk factors. We compared incidences of vascular diseases, vascular death, and
all-cause death after SAH with those in the general population.
Methods—From the Swedish Hospital Discharge and Cause of Death registries, we identified patients with SAH between
January 1987 and January 2003. Conditional on survival of 3 months after SAH, we calculated standardized mortality
and incidence ratios with corresponding 95% CIs for vascular death, all-cause death, and fatal or nonfatal vascular
diseases. Cumulative risks were estimated with survival analysis.
Results—Of 17 705 patients with SAH (mean age, 59.7 years; 59.5% women), 11 374 survived at least 3 months after
SAH. During follow-up (mean, 6.8 years), 2152 (18.9%) died. The risk of death was 12.9% within 5 years, 23.6% within
10 years, and 35.4% within 15 years after SAH. The overall standardized mortality ratio was 1.57 (95% CI, 1.44 to 1.70)
for vascular death and 1.61 (95% CI, 1.52 to 1.70) for all-cause death. The standardized mortality ratios were
particularly high in younger individuals, ranging from 2.1 to 3.7 for vascular death and from 2.1 to 2.6 for all-cause
death for patients between 50 and 65 years of age. The standardized incidence ratio for fatal or nonfatal vascular diseases
was 1.51 (95% CI, 1.45 to 1.56).
Conclusions—Mortality and risk of vascular diseases are increased in survivors of SAH. Prevention of new vascular
diseases after SAH by management of risk factors seems important. (Stroke. 2011;42:902-907.)
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Aneurysmal subarachnoid hemorrhage (SAH) used to beconsidered a once-in-a-lifetime event, but patients who
survive an SAH have an increased risk of developing new
intracranial aneurysms and new episodes of SAH.1,2 Because
hypertension and smoking are important risk factors for
SAH,3 people who survive SAH may also carry an increased
risk for other vascular diseases. Indeed, in a Finnish prospec-
tive cohort study4 and in the International Subarachnoid
Aneurysm Trial,5 survivors of SAH had an increased mortal-
ity compared with that of the general population. In those 2
studies, cerebrovascular diseases other than recurrent SAH
and cardiovascular diseases were important causes of death,
which suggests that the increased mortality after SAH is
caused by other vascular diseases. In another prospective
cohort study, mortality was also increased after surviving
SAH, but in that study, the risk of vascular events after SAH
was lower than in a sex- and age-matched cohort of patients
with a transient ischemic attack or minor stroke.6 The
included numbers of patients in those studies, however, were
not very large, and they concerned only patients in whom the
aneurysm was treated. Detailed and accurate information on
age- and sex-specific risks, vascular disease subtypes, and
nonfatal vascular diseases requires large numbers of patients
with long-term follow-up. Because individual hospitals and
even multicenter studies include too few patients with SAH
for accurate estimates, large patient registers with reliable
follow-up are needed. In Sweden, discharge and cause-of-
death registers cover all inpatient care and causes of death for
all Swedish citizens. These registers are a reliable and valid
source of data.7–10
For this report, we determined the long-term risks of
vascular death, all-cause death, and first vascular events in
Swedish SAH survivors and compared these risks with those
in the general Swedish population.
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Methods
SAH Patients
The Swedish Hospital Discharge Register covers all inpatient care in
Sweden from 1987 onward. The registry holds prospectively col-
lected data on main diagnosis (the principal cause of hospital stay),
secondary diagnoses indicating comorbidity, sex and age of the patients,
and dates of admission and discharge. All Swedish citizens have a
unique identification number. Until 1996, the Swedish version of the 9th
revision of the World Health Organization’s International Classification
of Diseases (ICD-9) was used; ICD-10 was introduced in 1997.
We searched all records for the diagnosis of SAH on the basis of
ICD codes 430 (ICD-9) and I60 (ICD-10). To limit selection bias,
only patients discharged with SAH as a main diagnosis were
selected. In total, 15 782 patients with SAH who were18 years old
at the time of the hemorrhage were identified from the period
January 1987 to January 2003.
The Swedish Cause of Death Register holds records of the
underlying and contributing causes of death for all Swedish citizens.
Data from 5233 patients with SAH as the cause of death between
January 1987 and January 2003 who were 18 years old at the time
of death were retrieved. Of these, 3310 patients were also registered
in the Hospital Discharge Register. After combining data from the 2
registers, we identified 17 705 patients with SAH as the main
discharge diagnosis or with SAH as the cause of death.
Reference Population
We used the entire Swedish population as the reference population.
Data were extracted from the Web site of the National Board of
Health and Welfare (http://www.socialstyrelsen.se) and from the
Web site of Statistics Sweden (http://www.scb.se). Data on hospital
admissions were available for the years 1998 to 2002; data on cause of
death were available for the years 1997 to 2002. The Swedish popula-
tion increased from 8 897 619 in 1997 to 8 954 175 persons in 2002.
Outcome Events
The ICD codes that we used to retrieve outcome events are listed in
Table 1. The main outcome events were vascular death and all-cause
death. The vascular diseases included in the definition of vascular death
are given in Table 1. All-cause death was defined as death from any
cause. Additional outcome events were the composite of fatal and
nonfatal vascular diseases (defined as in vascular death).
Vascular events were included only when these concerned main
discharge diagnoses, because this increases the proportion of patients
accurately classified.8,11,12 Because the hospital discharge register
does not discriminate between first and recurrent events, only data
from the first mention of specific ICD codes were extracted.
Additionally, only vascular events or deaths that occurred later than
3 months after SAH were considered an outcome event to avoid
including complications from the initial SAH, such as delayed
cerebral ischemia.
Data Analysis
For SAH patients, person-time at risk was calculated as the time
between the SAH and censoring, vascular disease, or death. The
demographic large-scale method for calculating person-time within
dynamic populations was used to calculate person-time at risk in the
reference population. It was calculated as the sum of the mean size
of the reference population in the subsequent calendar years.
We calculated standardized mortality ratios (SMRs) with corre-
sponding 95% CIs for vascular death and for all-cause death that
occurred from 1997 until the end of 2002. For this purpose, we
compared vascular-specific mortality and all-cause mortality for the
cohort of patients with SAH with those in the general Swedish
population from the age of 20 onward in sex-specific age categories
of 5 years. Similarly, we calculated standardized incidence ratios for
the composite of fatal and nonfatal vascular diseases.
Cumulative risks with corresponding 95% CIs were estimated
with survival analysis. Patients who died of a nonvascular cause
were censored at the time of death in the analysis of vascular events.
By means of Cox regression analysis, we calculated age-adjusted
hazard ratios with 95% CIs of sex for the risk of vascular death and
all-cause death. In addition, we calculated age-stratified risk differ-
ences in vascular and all-cause mortality rates between patients with
SAH and the reference population.
To enable a comparison of the proportions of SAH patients who
died of a vascular cause with data reported in the literature, we
calculated the proportion of patients who died of vascular events,




ICD-9 Codes ICD-10 CodesNo. %
Hypertensive heart or renal disease* 23 0.2% 402–404 I11–I13
Myocardial infarction 524 4.6% 410 I21
Ischemic heart disease* 877 7.7% 410–414 I20–I25
Pulmonary heart disease and diseases
of the pulmonary circulation*
71 0.6% 415–417 I26–I28
Other forms of heart disease* 609 5.4% 420–429 I30–I52
Ischemic stroke 632 5.6% 434, 436 I63
Intracerebral hemorrhage 276 2.4% 431 I61
Cerebrovascular disease, limited*† 1385 12.2% 431–434, 436, 437 I61–I68
Cerebrovascular disease, all‡ 2224 19.6% 430–434, 436–438 I60–I69
Aortic aneurysm 87 0.8% 441 I71
Diseases of arteries, arterioles, and
capillaries*
297 2.6% 440–448 I70–I74, I77–I79
Retinal vascular occlusion* 4 0.0% 362,3 H34
Sudden death, cause unknown* 0 0.0% 798 R96
Renal failure* 64 0.6% 584–586 N17–N19
*Vascular death is defined as death from the composite of these vascular diseases.
†Cerebrovascular diseases other than SAH, transient ischemic attack, and sequelae of cerebrovascular disease.
‡Cerebrovascular diseases after including SAH and sequelae of cerebrovascular disease.
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after including SAH and late effects of cerebrovascular disease as a
cause of death in the analysis.
Results
Of the 17 705 SAH patients for whom we retrieved data
(mean age, 59.7 years; 59.5% women), 5620 (31.7%) had
died within 28 days and 6146 (34.7%), within 3 months. One
hundred eighty-five patients had survived the SAH but had a
follow-up period of 3 months in the registry. The cohort of
11 374 SAH patients who were alive after the initial 3 months
yielded a total follow-up of 77 217 patient-years. The mean
follow-up time was 6.8 years (SD4.4).
Table 2 shows age- and sex-specific numbers of outcome
events. Overall, 2152 patients (18.9%) had died during
follow-up (mortality rate of 27.8 per 1000 patient-years). In 914
of the 2152 patients (42.5%) who had died during follow-up, the
cause of death was vascular other than SAH or late effects of
cerebrovascular disease. Table 3 shows age- and sex-specific
SMRs for vascular death and all-cause death compared with
those of the general population. The SMRs for both sexes were
particularly high in younger individuals, with SMRs ranging
from 2.1 to 3.7 for vascular death and from 2.1 to 2.6 for
all-cause death for patients between 50 and 65 years of age.
Figure 1 shows cumulative risks of vascular death and all-cause
death. The risk of death was 12.9% within 5 years, 23.6% within
10 years, and 35.4% within 15 years after SAH. Figure 2 shows
yearly SMRs for all-cause death during follow-up. The increased
mortality risk decreased slightly during the first years after SAH
but then seemed to stabilize during the remaining follow-up
years. In age-adjusted multivariable Cox regression analyses,
male sex was an independent predictor of vascular death (hazard
ratio1.55; 95% CI, 1.36 to 1.76) and all-cause death (hazard
ratio1.42; 95% CI, 1.30 to 1.54).
After including SAH and late effects of cerebrovascular
diseases as vascular causes of death in the analysis, 1229 of
the 2152 patients (57.1%) who died during follow-up had a
vascular cause of death. The overall SMR for both sexes for
vascular death now was 1.94 (95% CI, 1.80 to 2.09). Table 4
shows vascular and all-cause mortality rates per 1000 patient-
years and the excess of vascular and all-cause deaths for SAH
patients in comparison with the general population.
Throughout the follow-up period, 2713 patients (23.9%) had
a fatal or nonfatal first vascular event (Table 2). The subtypes of
vascular diseases are shown in Table 1. The age-specific
ratios were increased for men with SAH in the age groups up
to 85 years and for women up to 80 years of age (Table 3).
The most prevalent vascular diseases were ischemic stroke
(632 patients) and acute myocardial infarction (524 patients).
The SMR for ischemic stroke was 3.4 (95% CI, 1.7 to 6.7)
and for acute myocardial infarction, it was 1.4 (95% CI, 1.1
to 1.8).
Discussion
Patients who survive the initial 3 months after SAH have
increased risks for vascular death, all-cause death, and fatal
and nonfatal vascular diseases. Absolute risk increases, con-
ditional on survival at 3 months after SAH, were most
pronounced in the older age groups, with the exception of the
oldest old (85 years). Thus, our study based on follow-up
data on 11 000 patients with SAH and 77 000 patient-years
with inherently accurate point estimates for risks and ratios













No. % No. % No. %
18–29 Women 228 1 0.4 4 1.8 17 7.5
Men 239 0 0.0 7 2.9 19 7.9
30–39 Women 556 2 0.4 16 2.9 60 10.8
Men 450 5 1.1 20 4.4 50 11.1
40–49 Women 1350 9 0.7 64 4.7 195 14.4
Men 1021 32 3.1 99 9.7 192 18.8
50–59 Women 1668 41 2.5 155 9.3 300 18.0
Men 1301 69 5.3 172 13.2 286 22.0
60–69 Women 1422 121 8.5 321 22.6 391 27.5
Men 965 116 12.0 273 28.3 327 33.9
70–79 Women 1016 195 19.2 402 39.6 387 38.1
Men 548 132 24.1 265 48.4 230 42.0
80 Women 417 134 32.1 233 55.9 181 43.4
Men 193 57 29.5 121 62.7 78 40.4
Total Women 6657 503 7.6 1195 18.0 1531 23.0
Men 4717 411 8.7 957 20.3 1182 25.1
904 Stroke April 2011
 at Rijksuniversiteit Groningen on June 20, 2011 stroke.ahajournals.orgDownloaded from 
shows that the previously suggested increased mortality rates
for SAH patients are real and demonstrate for the first time
that this increased mortality rate is at least in part caused by
an increased risk of vascular diseases. Ischemic stroke and
acute myocardial infarction contributed importantly to these
vascular diseases. We found that this increased risk of
vascular diseases applied not only to older but also to younger
patients. The decrease of SMR with increasing age is prob-
ably explained by the increased background risk of vascular
diseases in the general population with increasing age. Our
analysis with yearly SMRs shows that the increased risk is
stable over time and is not clustered in the first years after the
SAH. We performed separate analyses with and without SAH
and late effects of cerebrovascular diseases in the definition
Figure 1. Time to vascular death (light
grey line), all-cause death (black line), and
composite fatal and nonfatal vascular dis-
ease (dark grey line) from 3 months after
SAH onward.
Table 3. Age- and Sex-Specific Ratios for Vascular Death, All-Cause Death, and the Composite of Fatal and Nonfatal Vascular
Disease Compared With Those of the General Swedish Population
Age
Category, years
Vascular Death All-Cause Death
Composite of Fatal and Nonfatal
Vascular Disease
Women Men Women Men Women Men
Ratio 95% CI Ratio 95% CI Ratio 95% CI Ratio 95% CI Ratio 95% CI Ratio 95% CI
20–24 0 … 0 … 0 … 0 … 17.6 2.5–125 0 …
25–29 0 … 0 … 0 … 4.0 0.6–28.4 18.5 6.9–49.4 5.0 1.3–20.1
30–34 0 … 0 … 5.2 0.7–36.7 0 … 12.5 5.6–27.9 7.6 3.4–1.9
35–39 18.2 2.5–130 0 … 5.2 1.7–16.1 2.2 0.6–8.8 8.5 4.7–15.4 2.6 1.1–6.2
40–44 5.8 0.8–41.6 15.7 7.0–35.0 4.3 2.0–8.9 6.6 3.8–11.3 8.9 6.3–12.5 5.8 4.1–8.2
45–49 0 … 5.1 2.3–11.4 1.9 0.9–3.8 3.5 2.1–5.7 4.8 3.6–6.5 3.3 2.5–4.3
50–54 4.5 2.0–10.0 3.9 2.2–6.7 2.3 1.6–3.5 3.0 2.1–4.2 3.4 2.7–4.2 2.1 1.7–2.6
55–59 2.6 1.2–5.5 2.8 1.7–4.4 2.7 2.0–3.6 2.1 1.6–2.9 2.9 2.4–3.4 1.7 1.5–2.0
60–64 2.5 1.4–4.5 2.2 1.4–3.2 2.3 1.8–3.1 2.1 1.6–2.7 2.4 2.0–2.8 1.7 1.5–2.0
65–69 2.4 1.6–3.6 2.0 1.4–2.8 1.9 1.5–2.5 1.8 1.4–2.2 1.8 1.5–2.1 1.5 1.3–1.7
70–74 2.0 1.5–2.8 1.4 1.0–2.0 1.8 1.5–2.2 1.8 1.5–2.2 1.7 1.5–1.9 1.2 1.1–1.4
75–79 1.9 1.5–2.4 1.4 1.0–1.8 1.9 1.6–2.3 1.3 1.0–1.6 1.5 1.4–1.7 1.3 1.1–1.5
80–84 1.5 1.2–1.9 1.7 1.3–2.3 1.5 1.3–1.8 1.6 1.3–2.0 1.0 0.9–1.2 1.5 1.3–1.8
85 1.2 1.0–1.5 1.0 0.7–1.4 1.1 1.0–1.3 1.1 0.9–1.4 0.9 0.7–1.0 1.1 0.9–1.3
All ages 1.62 1.45–1.82 1.64 1.46–1.86 1.66 1.54–1.79 1.66 1.54–1.80 1.62 1.54–1.71 1.51 1.43–1.60
All ages* 1.57 1.44–1.70 … … 1.61 1.52–1.70 … … 1.51 1.45–1.56 … …
All ages† 2.10 1.91–2.32 1.92 1.72–2.15 … … … … … … … …
*All ages, women and men combined.
†Including SAH and late effects of cerebrovascular diseases as causes of death.
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of vascular diseases because we aimed to assess the excess of
cerebro- and cardiovascular diseases not related to SAH.
In general, there are some limitations regarding the accu-
racy of data from hospital discharge and death registers, but
we believe that in our study, the results are unaffected by such
limitations. Patient registers may contain errors in coding, but
we have no reason to believe that these differ between the
cohort of SAH survivors and the reference population.
Consequently, the ratios that we calculated between the group
of patients with SAH and the reference population will be
valid. To increase the accuracy of coding, we chose to limit
the identifying ICD code to the main diagnosis.8,11,12 This
would probably have led to an underestimation of the
absolute risks that we found. Another reason for an underes-
timation of absolute risks of vascular diseases is that nonfatal
outpatient vascular events have been missed; this probably
concerns conditions such as angina pectoris or transient
ischemic attacks in particular.13 We did not investigate
nonfatal recurrent SAH or other recurrent vascular diseases
because the use of the hospital discharge register precluded
accurate discrimination between first and recurrent events. To
avoid including complications from the initial SAH, we
registered only vascular events or deaths that occurred 3
months after the SAH, although this time period is arbitrary.
Figure 2. SMR per year, with correspond-
ing 95% CIs for all-cause death from 3
months after SAH onward.
Table 4. Vascular and All-Cause Mortality With Risk Differences per 1000 Patient-Years
Age
Category, years










20–24 0.0 0.0 0.0 0.5 0.0 (0.0 to 0.0) 0.5 (0.5 to0.5)
25–29 0.0 0.0 1.5 0.5 0.0 (0.0 to 0.0) 1.0 (1.9 to 3.9)
30–34 0.0 0.0 0.9 0.6 0.0 (0.1 to 0.0) 0.4 (1.5 to 2.2)
35–39 0.5 0.1 2.7 0.8 0.4 (0.6 to 1.5) 1.9 (0.5 to 4.2)
40–44 3.5 0.2 6.9 1.3 3.2 (1.1 to 5.4) 5.6 (2.6 to 8.6)
45–49 3.0 0.5 5.6 2.1 2.6 (0.9 to 4.2) 3.5 (1.2 to 5.7)
50–54 4.4 0.9 9.0 3.5 3.6 (1.9 to 5.2) 5.6 (3.2 to 7.9)
55–59 5.3 1.5 11.9 5.2 3.8 (2.1 to 5.5) 6.7 (4.2 to 9.3)
60–64 8.2 2.8 18.0 8.5 5.4 (3.1 to 7.7) 9.4 (6.1 to 12.8)
65–69 14.0 5.5 26.1 14.6 8.5 (5.3 to 11.7) 11.4 (7.0 to 15.8 )
70–74 21.5 10.4 42.8 24.7 11.1 (6.9 to 15.4 ) 18.1 (12.1 to 24.1)
75–79 39.7 19.9 65.8 42.3 19.8 (13.3 to 26.4 ) 23.6 (15.2 to 31.9 )
80–84 63.5 37.4 108.4 72.2 26.1 (14.8 to 37.3 ) 36.2 (21.5 to 50.8 )
85 115.4 93.9 189.5 171.8 21.5 (2.2 to 40.8 ) 17.6 (7.1 to 42.4 )
Unstandardized 15.2 6.5 27.8 13.8 8.7 (7.6 to 9.9 ) 14.0 (12.5 to 15.5 )
Standardized 15.2 7.8 27.8 17.3 7.4 (6.0 to 8.8 ) 10.5 (8.6 to 12.4 )
*Including SAH and late effects of cerebrovascular disease as causes of death.
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Several studies have shown that the Swedish registries are
a reliable and valid source of data.7–10 In a study in which
several patient identification strategies were investigated in 2
prospective cohorts of patients, the strategy of combining the
National Hospital Discharge Register and the National Cause
of Death Register gathered 98% of probable cases of myo-
cardial infarction and stroke.10 Another study in which the
validity of the diagnosis of heart failure was assessed dem-
onstrated a sensitivity of 95%.8 Other studies with the
Swedish registries reported high sensitivities and positive
predictive values for acute myocardial infarction and
stroke.7,9 Further data underlining the accuracy of the data of
our study are that the incidence of SAH found in the Swedish
patient registers is in line with the incidence found in Swedish
population-based studies.14,15 Also, the 1-month case-fatality
rate derived from the registries is identical to the case-fatality
rate from Swedish population-based studies (32%).16
Long-term follow-up data on patients surviving SAH are
sparse. Our study is by far the largest on this topic. A Finnish
prospective cohort study with 1537 SAH patients in whom
the ruptured aneurysm was treated yielded excess long-term
mortality after a median follow-up time of 7.5 years.4
Systemic cardiovascular disease appeared to be the most
important cause of death, responsible for 60% of cases. This
is comparable to the 57% that we found. We could not compare
our data with those on nonfatal vascular events or subtypes of
vascular disease because that information was lacking in the
Finnish study. The estimated survival rate of 15 years after SAH
was 65.6% in the Finnish study, which is also similar to the
64.6% that we found in our study. Recently published long-term
follow-up data from the International Subarachnoid Aneurysm
Trial concerning 2004 patients with a mean follow-up time of 9
years also showed increased death rates compared with those in
the general population in the United Kingdom.5 In the Interna-
tional Subarachnoid Aneurysm Trial, 12.3% of the patients had
died after 5 years of follow-up, which is in line with the 12.9%
found in our study. Again, data on nonfatal vascular events were
missing in that study, as well as age- and cause-specific SMRs.
A third study demonstrated excess long-term mortality (mean
follow-up of 8.1 years) in 752 patients with SAH.6 The risk of
vascular events after SAH was lower than that after minor stroke
but seemed to be higher in an indirect comparison with the
general population. In this study, only patients who were clipped
and who recovered to a functional independent state were
included.
A possible explanation for the high risk of developing new
vascular diseases after SAH is that smoking and hypertension
are common risk factors for both SAH and ischemic cardio-
vascular disease and other stroke subtypes.3,17 The increased
risk of vascular diseases and the inherent increased mortality
ratio of patients who have survived an episode of SAH
indicates that it is important to insist on cessation of smoking
and stringent management of hypertension and other risk
factors. Whether these patients would benefit from antiplate-
let agents, antihypertensive drugs, and statins should be
assessed in a future clinical trial.
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